Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix's Q4 Revenues Slide 6.5 Percent as Profit Plummets 72 Percent

NEW YORK (GenomeWeb News) —Affymetrix today said fourth-quarter revenues decreased 6.5 percent as R&D spending remained flat and profit plummeted 72 percent.
 
Total receipts for the three months ended Dec. 31, 2006, decreased to $104.2 million from $111.4 million year over year.
 
Product and product-related revenue decreased 9.5 percent to $95 million; royalties and "other" revenue increased 115 percent to $6.6 million; and receipts from Perlegen slid 5.5 percent to $2.6 million.
 
R&D spending was flat at $19.6 million.
 
The company said profit declined to $8.7 million from $30.6 million in the year-ago period.
 
Affy said it had around $119 million in cash and equivalents and $118 million in short-term investments as of Dec. 31.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.